cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.5281/zenodo.7533669
title: Dataset for "Strong coupling between a photon and a hole spin in silicon"

description: This dataset contains the raw data and its analysis code to generate the figures of the publication entitled : "Strong coupling between a photon and a hole spin in silicon". Please have a look at the readme.txt file for further information.
DOI: 10.5281/zenodo.7533668
title: Dataset for "Strong coupling between a photon and a hole spin in silicon"

description: This dataset contains the raw data and its analysis code to generate the figures of the publication entitled : "Strong coupling between a photon and a hole spin in silicon". Please have a look at the readme.txt file for further information.
DOI: 10.6084/m9.figshare.21895983
title: scRNA-seq on iPSC-derived microglia

description: scRNA-seq of iPSC-microglia (pseudo-bulk) Pseudo-bulk from processed single-cell RNA-seq data from uninfected iPSC-derived microglia (comprising protein-coding genes). <br>
DOI: 10.6084/m9.figshare.21895983.v1
title: scRNA-seq on iPSC-derived microglia

description: scRNA-seq of iPSC-microglia (pseudo-bulk) Pseudo-bulk from processed single-cell RNA-seq data from uninfected iPSC-derived microglia (comprising protein-coding genes). <br>
DOI: 10.25835/9yuakupi
title: Machine and Tool Ontology

description: The Machine and Tool Ontology (MATO) represents a semantic model for the general description of equipment used in the development of production technologies. The equipment is described by properties like manufacturer, model, physical location, and a specific application area, as well as by using freely formulated expressions in natural language. MATO enables the expression of possible combinations of different equipment types required to fulfill a specific action. Furthermore, MATO semantically relates equipment with agents such as persons and organizations responsible for them.
DOI: 10.5281/zenodo.7533370
title: Therapy With Different Dose Regimens of Rituximab in Patients With Active Moderate-To-Severe Graves' Orbitopathy

description: Abstract <strong>Background: </strong>Immunosuppressive therapy of Graves' orbitopathy (GO) is indicated during the active phase of disease. Intravenous steroids (IVGC) are effective in about 70% of patients, although unresponsiveness or relapse are observed. In previous studies, rituximab (RTX) has been shown to be effective in inactivating moderate-to-severe GO when used early in the disease, but its optimal dosage has never been studied in randomized clinical trials. Aim of this study was to compare the efficacy and safety of different doses of RTX, based on a <em>post-hoc</em> analysis of two open label studies and one prospective trial randomized to IVGC. <strong>Methods: </strong>of 40 patients (35 women, 5 men), with active moderate-to-severe GO treated with RTX, 14 received a single dose of 100 mg (Group 1), 15 a single dose of 500 mg (Group 2) and 11 two 1000 mg doses, administered one week apart (Group 3). Thyroid function, TSH-receptor antibodies (TRAb) and peripheral CD19+ cells were measured. Primary endpoint was disease inactivation, measured as a decrease of the Clinical Activity Score (CAS) of at least two points. Secondary endpoints were improvement of proptosis, diplopia, quality of life and safety. <strong>Results: </strong>Baseline CAS decreased significantly in all groups (P&lt;0.0001), independently of GO duration or whether patients had newly occurring or relapsing GO after IVGC. Proptosis did not significantly change. There was an inverse correlation between the Gorman score for diplopia and RTX dose (P&lt;0.01). The appearance score of the GO-QoL improved in Group 1 (P=0.015), and the visual function score, in Group 2 (P=0.04). A reduction of serum TRAb was observed in Group 1 (P=0.002) and Group 2 (P&lt;0.0002), but not in Group 3. CD19+ cell decreased in all groups (P&lt;0.01), independently of the dose. <strong>Conclusions: </strong>We studied the optimal dosage of RTX in the treatment of active moderate-to-severe GO. In this analysis, we considered the efficacy of RTX in inactivating GO, in changing its natural course, its effect on disease severity and on the patients' quality of life. Based on our clinical findings, and balancing the cost of therapy, a single 500 mg dose regimen is suggested in the majority of patients.
DOI: 10.5281/zenodo.7533369
title: Therapy With Different Dose Regimens of Rituximab in Patients With Active Moderate-To-Severe Graves' Orbitopathy

description: Abstract <strong>Background: </strong>Immunosuppressive therapy of Graves' orbitopathy (GO) is indicated during the active phase of disease. Intravenous steroids (IVGC) are effective in about 70% of patients, although unresponsiveness or relapse are observed. In previous studies, rituximab (RTX) has been shown to be effective in inactivating moderate-to-severe GO when used early in the disease, but its optimal dosage has never been studied in randomized clinical trials. Aim of this study was to compare the efficacy and safety of different doses of RTX, based on a <em>post-hoc</em> analysis of two open label studies and one prospective trial randomized to IVGC. <strong>Methods: </strong>of 40 patients (35 women, 5 men), with active moderate-to-severe GO treated with RTX, 14 received a single dose of 100 mg (Group 1), 15 a single dose of 500 mg (Group 2) and 11 two 1000 mg doses, administered one week apart (Group 3). Thyroid function, TSH-receptor antibodies (TRAb) and peripheral CD19+ cells were measured. Primary endpoint was disease inactivation, measured as a decrease of the Clinical Activity Score (CAS) of at least two points. Secondary endpoints were improvement of proptosis, diplopia, quality of life and safety. <strong>Results: </strong>Baseline CAS decreased significantly in all groups (P&lt;0.0001), independently of GO duration or whether patients had newly occurring or relapsing GO after IVGC. Proptosis did not significantly change. There was an inverse correlation between the Gorman score for diplopia and RTX dose (P&lt;0.01). The appearance score of the GO-QoL improved in Group 1 (P=0.015), and the visual function score, in Group 2 (P=0.04). A reduction of serum TRAb was observed in Group 1 (P=0.002) and Group 2 (P&lt;0.0002), but not in Group 3. CD19+ cell decreased in all groups (P&lt;0.01), independently of the dose. <strong>Conclusions: </strong>We studied the optimal dosage of RTX in the treatment of active moderate-to-severe GO. In this analysis, we considered the efficacy of RTX in inactivating GO, in changing its natural course, its effect on disease severity and on the patients' quality of life. Based on our clinical findings, and balancing the cost of therapy, a single 500 mg dose regimen is suggested in the majority of patients.
DOI: 10.5281/zenodo.7533565
title: A Non-parametric Discrete Fracture Network Model

description: Database used to build discrete fracture networks through a non-parametric approach from Gómez et al. 2023 (DOI: 10.1007/s00603-022-03194-y). The data is structured in twelve.csv files, each with an array of size n-by-3, containing the orientation of the discontinuity (dip direction and dip of the pole) and its pseudo-trace length in meters, with n being the number of fractures in each file.
description: {"references": ["Gomez et al. 2023. 10.1007/s00603-022-03194-y"]}
DOI: 10.5281/zenodo.7533564
title: A Non-parametric Discrete Fracture Network Model

description: Database used to build discrete fracture networks through a non-parametric approach from Gómez et al. 2023 (DOI: 10.1007/s00603-022-03194-y). The data is structured in twelve.csv files, each with an array of size n-by-3, containing the orientation of the discontinuity (dip direction and dip of the pole) and its pseudo-trace length in meters, with n being the number of fractures in each file.
description: {"references": ["Gomez et al. 2023. 10.1007/s00603-022-03194-y"]}
DOI: 10.6084/m9.figshare.21896187
title: Original data used to calculate PCEC-EIs

description: Provincial GDP, year-end population, industrial added value, forestry land areas, construction land areas, and agricultural land areas were derived from the <em>China Statistical Yearbook 2020.</em> Provincial R & D funding was obtained from the <em>2019 statistical bulletin of national science and technology investment. </em>The <em>China Energy Statistical Yearbook 2020 </em>provided data on provincial total energy consumption, coal-dominated energy consumption, gross electricity generation, and renewable electricity generation (including hydro, nuclear, wind, and solar). The provincial industrial and household energy consumption was calculated using the provincial energy balance sheet from the <em>China Energy Statistical Yearbook 2020</em> and the reference coefficients of various energy sources converted into standard coal provided by the Ministry of Industry and Information Technology.
DOI: 10.6084/m9.figshare.21896187.v1
title: Original data used to calculate PCEC-EIs

description: Provincial GDP, year-end population, industrial added value, forestry land areas, construction land areas, and agricultural land areas were derived from the <em>China Statistical Yearbook 2020.</em> Provincial R & D funding was obtained from the <em>2019 statistical bulletin of national science and technology investment. </em>The <em>China Energy Statistical Yearbook 2020 </em>provided data on provincial total energy consumption, coal-dominated energy consumption, gross electricity generation, and renewable electricity generation (including hydro, nuclear, wind, and solar). The provincial industrial and household energy consumption was calculated using the provincial energy balance sheet from the <em>China Energy Statistical Yearbook 2020</em> and the reference coefficients of various energy sources converted into standard coal provided by the Ministry of Industry and Information Technology.
DOI: 10.5281/zenodo.6272007
title: Dataset and tool - A Static Analysis for Discovering Type-Related Coding Idioms in Python Programs

description: The archive file contains the following materials: `repos.tar.gz`: dataset of the collected Python repositories `tool.tar.gz`: programs used in the case studies
DOI: 10.5281/zenodo.6272008
title: Dataset and tool - A Static Analysis for Discovering Type-Related Coding Idioms in Python Programs

description: The archive file contains the following materials: `repos.tar.gz`: dataset of the collected Python repositories `tool.tar.gz`: programs used in the case studies
DOI: 10.5281/zenodo.7533282
title: Dataset and tool - A Static Analysis for Discovering Type-Related Coding Idioms in Python Programs

description: The archive file contains the following materials: `repos.tar.gz`: dataset of the collected Python repositories `tool.tar.gz`: programs used in the case studies
DOI: 10.3886/e148301v1-131784
title: Data and code for "Multinationals' Sales and Profit Shifting in Tax Havens."

description: We show that U.S. multinationals record sales and the profit from these sales in tax havens, while their goods and services are physically sold in other countries. We propose a framework illustrating the strategy of sales shifting. Our results reveal the importance of tax havens which attract a disproportionate fraction of worldwide sales. Our quantification shows a large contribution of sales shifting to multinationals' profit shifting that amounts to $80bn in 2013. Our findings suggest that international corporate tax rules based on sales may not efficiently address profit shifting if the policy designs are unable to identify sales by destination.<br><br>
description: <br>U.S. Multinational Firms Abroad<br>. Smallest Geographic Unit: Countries
DOI: 10.5281/zenodo.6798083
title: Data of FigS2, "The Potential Tumor-Suppressor DHRS7 Inversely Correlates with EGFR Expression in Prostate Cancer Cells and Tumor Samples"

description: Data of FigS2, “The Potential Tumor-Suppressor DHRS7 Inversely Correlates with EGFR Expression in Prostate Cancer Cells and Tumor Samples” The Dataset (original publication: doi: 10.3390/cancers14133074) contains the original figure as PNG-format (10.3390-cancers14133074_FigS2.PNG). The corresponding raw data and subsequent data analysis obtained from proteomics analysis are provided as nine files in CSV format (31003A-179400_10.3390-cancers14133074_SS_SA_DHRS7_5_1-3_M1-3.csv). All further experiment related information provided as one meta-data-file (31003A-179400_10.3390-cancers14133074_SS_SA_DHRS7_5_1_M .txt) in txt format.
DOI: 10.5281/zenodo.6798084
title: Data of FigS2, "The Potential Tumor-Suppressor DHRS7 Inversely Correlates with EGFR Expression in Prostate Cancer Cells and Tumor Samples"

description: Data of FigS2, “The Potential Tumor-Suppressor DHRS7 Inversely Correlates with EGFR Expression in Prostate Cancer Cells and Tumor Samples” The Dataset (original publication: doi: 10.3390/cancers14133074) contains the original figure as PNG-format (10.3390-cancers14133074_FigS2.PNG). The corresponding raw data and subsequent data analysis obtained from proteomics analysis are provided as nine files in CSV format (31003A-179400_10.3390-cancers14133074_SS_SA_DHRS7_5_1-3_M1-3.csv). All further experiment related information provided as one meta-data-file (31003A-179400_10.3390-cancers14133074_SS_SA_DHRS7_5_1_M .txt) in txt format.
DOI: 10.5281/zenodo.6797549
title: Data of Fig2, "The Potential Tumor-Suppressor DHRS7 Inversely Correlates with EGFR Expression in Prostate Cancer Cells and Tumor Samples"

description: Data of Fig2, “The Potential Tumor-Suppressor DHRS7 Inversely Correlates with EGFR Expression in Prostate Cancer Cells and Tumor Samples” The Dataset (original publication: doi: 10.3390/cancers14133074) contains the original figure as PNG-format (10.3390-cancers14133074_Fig2.PNG). The corresponding raw data and subsequent data analysis obtained from proteomics analysis are provided as three files in CSV format (31003A-179400_10.3390-cancers14133074_SS_SA_DHRS7_5_1-3.csv). All further experiment related information provided as one meta-data-file (31003A-179400_10.3390-cancers14133074_SS_SA_DHRS7_5_1_M .txt) in txt format. Corresponding raw data and subsequent data analysis obtained from western blot analysis contains the original figures of the raw blots and antibody dilutions as PDF-format (31003A-179400_10.3390-cancers14133074_SSDHRS7_2_1_M_1 .pdf), data analysis (densitometry) and all further experiment related information provided as one meta-data-file in txt format (31003A-179400_10.3390-cancers14133074_SSDHRS7_2_1_M.txt). Corresponding raw data and subsequent data analysis obtained from RT-PCR analysis provided as one files in TXT format (31003A-179400_10.3390-cancers14133074_SSDHRS7_1_2_M.txt), all further experiment related information provided as one meta-data-file in pdf format (31003A-179400_10.3390-cancers14133074_SSDHRS7_1_2_M_1.pdf).
DOI: 10.5281/zenodo.6797550
title: Data of Fig2, "The Potential Tumor-Suppressor DHRS7 Inversely Correlates with EGFR Expression in Prostate Cancer Cells and Tumor Samples"

description: Data of Fig2, “The Potential Tumor-Suppressor DHRS7 Inversely Correlates with EGFR Expression in Prostate Cancer Cells and Tumor Samples” The Dataset (original publication: doi: 10.3390/cancers14133074) contains the original figure as PNG-format (10.3390-cancers14133074_Fig2.PNG). The corresponding raw data and subsequent data analysis obtained from proteomics analysis are provided as three files in CSV format (31003A-179400_10.3390-cancers14133074_SS_SA_DHRS7_5_1-3.csv). All further experiment related information provided as one meta-data-file (31003A-179400_10.3390-cancers14133074_SS_SA_DHRS7_5_1_M .txt) in txt format. Corresponding raw data and subsequent data analysis obtained from western blot analysis contains the original figures of the raw blots and antibody dilutions as PDF-format (31003A-179400_10.3390-cancers14133074_SSDHRS7_2_1_M_1 .pdf), data analysis (densitometry) and all further experiment related information provided as one meta-data-file in txt format (31003A-179400_10.3390-cancers14133074_SSDHRS7_2_1_M.txt). Corresponding raw data and subsequent data analysis obtained from RT-PCR analysis provided as one files in TXT format (31003A-179400_10.3390-cancers14133074_SSDHRS7_1_2_M.txt), all further experiment related information provided as one meta-data-file in pdf format (31003A-179400_10.3390-cancers14133074_SSDHRS7_1_2_M_1.pdf).
DOI: 10.5281/zenodo.6797489
title: Data of Fig1, "The Potential Tumor-Suppressor DHRS7 Inversely Correlates with EGFR Expression in Prostate Cancer Cells and Tumor Samples"

description: Data of Fig1, “The Potential Tumor-Suppressor DHRS7 Inversely Correlates with EGFR Expression in Prostate Cancer Cells and Tumor Samples” The Dataset (doi: 10.3390/cancers14133074) contains the original figures as PNG-format (10.3390-cancers14133074_Fig1.PNG). Raw data and related Meta data are provides as one file in TXT format (31003A-179400_10.3390-cancers14133074_SSDHRS7_1_1_M.txt) and one file in PDF-Format (31003A-179400_10.3390-cancers14133074_SSDHRS7_1_1_M_1.pdf).
DOI: 10.5281/zenodo.6797490
title: Data of Fig1, "The Potential Tumor-Suppressor DHRS7 Inversely Correlates with EGFR Expression in Prostate Cancer Cells and Tumor Samples"

description: Data of Fig1, “The Potential Tumor-Suppressor DHRS7 Inversely Correlates with EGFR Expression in Prostate Cancer Cells and Tumor Samples” The Dataset (doi: 10.3390/cancers14133074) contains the original figures as PNG-format (10.3390-cancers14133074_Fig1.PNG). Raw data and related Meta data are provides as one file in TXT format (31003A-179400_10.3390-cancers14133074_SSDHRS7_1_1_M.txt) and one file in PDF-Format (31003A-179400_10.3390-cancers14133074_SSDHRS7_1_1_M_1.pdf).
DOI: 10.5517/ccdc.csd.cc291s27
title: CCDC 2116868: Experimental Crystal Structure Determination

description: Related Article: Pierre Thuéry, Jack Harrowfield|2021|Eur.J.Inorg.Chem.|2022|e202100917|doi:10.1002/ejic.202100917
description: An entry from the Cambridge Structural Database, the world’s repository for small molecule crystal structures. The entry contains experimental data from a crystal diffraction study. The deposited dataset for this entry is freely available from the CCDC and typically includes 3D coordinates, cell parameters, space group, experimental conditions and quality measures.
DOI: 10.5517/ccdc.csd.cc291s38
title: CCDC 2116869: Experimental Crystal Structure Determination

description: Related Article: Pierre Thuéry, Jack Harrowfield|2021|Eur.J.Inorg.Chem.|2022|e202100917|doi:10.1002/ejic.202100917
description: An entry from the Cambridge Structural Database, the world’s repository for small molecule crystal structures. The entry contains experimental data from a crystal diffraction study. The deposited dataset for this entry is freely available from the CCDC and typically includes 3D coordinates, cell parameters, space group, experimental conditions and quality measures.
DOI: 10.5517/ccdc.csd.cc291s49
title: CCDC 2116870: Experimental Crystal Structure Determination

description: Related Article: Pierre Thuéry, Jack Harrowfield|2021|Eur.J.Inorg.Chem.|2022|e202100917|doi:10.1002/ejic.202100917
description: An entry from the Cambridge Structural Database, the world’s repository for small molecule crystal structures. The entry contains experimental data from a crystal diffraction study. The deposited dataset for this entry is freely available from the CCDC and typically includes 3D coordinates, cell parameters, space group, experimental conditions and quality measures.
DOI: 10.5517/ccdc.csd.cc291s5b
title: CCDC 2116871: Experimental Crystal Structure Determination

description: Related Article: Pierre Thuéry, Jack Harrowfield|2021|Eur.J.Inorg.Chem.|2022|e202100917|doi:10.1002/ejic.202100917
description: An entry from the Cambridge Structural Database, the world’s repository for small molecule crystal structures. The entry contains experimental data from a crystal diffraction study. The deposited dataset for this entry is freely available from the CCDC and typically includes 3D coordinates, cell parameters, space group, experimental conditions and quality measures.
DOI: 10.5517/ccdc.csd.cc291s6c
title: CCDC 2116872: Experimental Crystal Structure Determination

description: Related Article: Pierre Thuéry, Jack Harrowfield|2021|Eur.J.Inorg.Chem.|2022|e202100917|doi:10.1002/ejic.202100917
description: An entry from the Cambridge Structural Database, the world’s repository for small molecule crystal structures. The entry contains experimental data from a crystal diffraction study. The deposited dataset for this entry is freely available from the CCDC and typically includes 3D coordinates, cell parameters, space group, experimental conditions and quality measures.
DOI: 10.5517/ccdc.csd.cc291s7d
title: CCDC 2116873: Experimental Crystal Structure Determination

description: Related Article: Pierre Thuéry, Jack Harrowfield|2021|Eur.J.Inorg.Chem.|2022|e202100917|doi:10.1002/ejic.202100917
description: An entry from the Cambridge Structural Database, the world’s repository for small molecule crystal structures. The entry contains experimental data from a crystal diffraction study. The deposited dataset for this entry is freely available from the CCDC and typically includes 3D coordinates, cell parameters, space group, experimental conditions and quality measures.
DOI: 10.5517/ccdc.csd.cc291s8f
title: CCDC 2116874: Experimental Crystal Structure Determination

description: Related Article: Pierre Thuéry, Jack Harrowfield|2021|Eur.J.Inorg.Chem.|2022|e202100917|doi:10.1002/ejic.202100917
description: An entry from the Cambridge Structural Database, the world’s repository for small molecule crystal structures. The entry contains experimental data from a crystal diffraction study. The deposited dataset for this entry is freely available from the CCDC and typically includes 3D coordinates, cell parameters, space group, experimental conditions and quality measures.
DOI: 10.5517/ccdc.csd.cc28qtlf
title: CCDC 2107305: Experimental Crystal Structure Determination

description: Related Article: Javier Martí-Rujas, Stefano Elli, Alessandro Sacchetti, Franca Castiglione|2021|Dalton Trans.|51|53|doi:10.1039/D1DT03158A
description: An entry from the Cambridge Structural Database, the world’s repository for small molecule crystal structures. The entry contains experimental data from a crystal diffraction study. The deposited dataset for this entry is freely available from the CCDC and typically includes 3D coordinates, cell parameters, space group, experimental conditions and quality measures.
DOI: 10.5517/ccdc.csd.cc29lg1f
title: CCDC 2132894: Experimental Crystal Structure Determination

description: Related Article: Pierre Thuéry, Jack Harrowfield|2022|Eur.J.Inorg.Chem.|2022|e202200011|doi:10.1002/ejic.202200011
description: An entry from the Cambridge Structural Database, the world’s repository for small molecule crystal structures. The entry contains experimental data from a crystal diffraction study. The deposited dataset for this entry is freely available from the CCDC and typically includes 3D coordinates, cell parameters, space group, experimental conditions and quality measures.
DOI: 10.5517/ccdc.csd.cc29lg2g
title: CCDC 2132895: Experimental Crystal Structure Determination

description: Related Article: Pierre Thuéry, Jack Harrowfield|2022|Eur.J.Inorg.Chem.|2022|e202200011|doi:10.1002/ejic.202200011
description: An entry from the Cambridge Structural Database, the world’s repository for small molecule crystal structures. The entry contains experimental data from a crystal diffraction study. The deposited dataset for this entry is freely available from the CCDC and typically includes 3D coordinates, cell parameters, space group, experimental conditions and quality measures.